Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01412372 · ClinicalTrials.gov registry record · Phase 3
The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
A Phase 3 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT01412372 is a Phase 3 study that has completed, run by University of Utah. The registered enrollment target is 61 participants.
The verdict
NCT01412372, a Phase 3 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of long acting mesalamine (Lialda) in patients with Post-Infective Irritable Bowel Syndrome (PI-IBS). The investigators will evaluate gastrointestinal symptoms, IBS specific quality of life (IBS-QOL), and plasma cytokines before and after treatment with Lialda.
Interventions
- DRUG Placebo
- DRUG Mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-06 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01412372
The ClinicalTrials.gov registry entry for NCT01412372 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01412372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01412372 about?
NCT01412372 is a clinical study titled "The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study". The purpose of this study is to evaluate the effects of long acting mesalamine (Lialda) in patients with Post-Infective Irritable Bowel Syndrome (PI-IBS). The investigators will evaluate gastrointestinal symptoms, IBS specific quality of life (IBS-QOL), and plasma cytokines before and after treatmen...
What is the current status of trial NCT01412372?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2010-06. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT01412372?
The interventions under investigation include: Placebo (DRUG), Mesalamine (DRUG).
Who is sponsoring clinical trial NCT01412372?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.